The same event can reach both: a study opening is one line under its program in the brief, and one study’s change in the alerts.
The registry lists 2,442 studies for Brain Neoplasms across more than 10 countries. 543 are recruiting or about to start. 1,204 of them are mainly about Brain Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 9 narrower conditions too, such as Pituitary Neoplasms: 2,894 studies, 659 open.
ClinicalTrials.gov finds 4,501 studies for Brain Neoplasms.How that becomes 2,441 hereChecked on ClinicalTrials.gov . The studies here are updated every night.
This page counts the studies the registry files under Brain Neoplasms, and those it files under no condition that list Brain Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. Only this comparison waits for its turn: it is asked again about once a week, so between two checks the registry's number can run a little ahead of it. How condition pages count
4,501Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−81List Brain Neoplasms as a condition, but the registry did not file them under itMost often written as “Brain Tumor Adult” (14), “Pediatric Brain Tumor” (10), and “Childhood Brain Tumor” (9). The registry filed them under other conditions only, most often Neoplasms (18) and Glioma (12).
−1,598Match it another way283 name it in the title, 30 in a keyword, and 1,285 by a synonym or other text the search reads.
2,436Counted here and found by its search64 of them list Brain Neoplasms in their own words; the registry filed them under no condition.
Every program with a company-led study here in the last two years, whatever its size: 20 programs from 19 companies, 8 with this as their studies’ main aim; 2 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Telix Pharmaceuticals, BioNTech and Bristol-Myers Squibb here →
Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.
Comparator & background therapies
What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.
“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.
The 1 in phase 3 with the nearest primary completion, of 20 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.
Primary completion in the next 12 months (2)
Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.
15 Jan 2027 est.desoxyepothilone B· Biostar Pharma, Inc. · Phase 2named, not the main aimNCT06764940 A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases — primary endpoint: Intracranial Objective Response Rate (IC-ORR) evaluated by investigator according to RECIST 1.1 criteria. · 120 enrolled
31 Mar 2027 est.PRMT5 Inhibitor TNG456· Tango Therapeutics, Inc. · Phase 2named, not the main aimstudied with abemaciclibNCT06810544 Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss — primary endpoint: Phase 1 Maximum Tolerated Dose · 191 enrolled
Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.
What is being tested here
Drugs under test in Brain Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
237studies finish main data collection within a year15 of them phase 3
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Of the 427 Brain Neoplasms studies recruiting now, 287 (67%) set no upper age limit and 82 (19%) stop at 75 or younger. 80 (19%) take children under 18. 8 (2%) are for women only and 1 (<1%) for men only; 37 (9%) take healthy volunteers.
Across all 2,442 studies, recruiting or not: 22% stop at 75 or younger and 15% at 65; 21% take children; 2% are for women only and <1% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Brain Neoplasms studies take
Of 252 phase 2 interventional studies under Brain Neoplasms, half reached primary completion within 61 months of starting, counting those still running.
Start to primary completion
Every sponsor
Industry
Non-industry
Phase 1
54 mo36–84 · 204 studies
—
56 mo36–84 · 176 studies
Phase 1/2
82 mo48–105 · 73 studies
—
85 mo50–105 · 50 studies
Phase 2
61 mo38–98 · 252 studies
43 mo24–55 · 44 studies
67 mo43–100 · 208 studies
Phase 3
81 mo48–269 · 56 studies
—
—
Interventional, no phase
64 mo35–125 · 318 studies
—
65 mo36–126 · 307 studies
Observational
82 mo41–269 · 200 studies
—
82 mo42–269 · 182 studies
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 19, 2026.